Comparison of Efficacy and Cost-Effectiveness of Filgrastim, tbo-Filgrastim, and Filgrastim-sndz in Patients with Cancer Receiving Myelosuppressive Chemotherapy and Patients with Severe Chronic Neutropenia

ASHP 2016 - ASHP 2016 - Oncology, Conference Correspondent

Colony-stimulating factors (CSFs) have been used in the United States since 1991, since the approval of filgrastim, and regulate the production of neutrophils within the bone marrow. CSFs are indicated for use in cancer patients receiving myelosuppressive chemotherapy, patients with acute myeloid leukemia receiving induction or consolidation chemotherapy, cancer patients receiving bone marrow transplant, patients undergoing peripheral blood progenitor cell collection and therapy, and patients with severe chronic neutropenia. The objective of this study is to compare the efficacy, cost, and adverse effects of filgrastim, tbo-filgrastim, and filgrastim-sndz in a community hospital.

All 3 CSFs are currently being used at Indian River Medical Center (IRMC), and the data have been collected through the IRMC electronic medical record to compare the efficacy, cost, and adverse effects of the 3 products. The following data will be collected: age, sex, ethnicity, white blood cell (WBC) trends, absolute neutrophil count (ANC) trends, intravenous anti-infective use, incidence of bone pain, incidence of nausea, length of stay, and hospital costs. They also will review the 6 months of utilization data for each product: filgrastim, tbo-filgrastim, and filgrastim-sndz.

The investigators’ primary outcome will be the comparison of WBC count and ANC trends among the 3 products, and the difference in the length of stay and hospital costs among patients receiving each medication. The secondary end point that will be tested is the incidence of bone pain and nausea of each CSF product. The efficacy and cost-effectiveness of each product will be evaluated using the student t test and chi square analysis. The investigators anticipate the study will begin in early 2017.

Patel M. Abstract presented at ASHP Midyear Clinical Meeting. Las Vegas, NV; December 2016.

Related Items
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates & News, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, AONN+ News
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Combining Immunotherapy and Radiotherapy Shows Good Synergy
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Immunotherapy, Conference Correspondent
Quizartinib Combinations Show High Activity in Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates & News
Humanizing Cancer Care: The Patient Perspective
Gail Thompson
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ACCC
Emerging Safety Data with Checkpoint Inhibitors
Phoebe Starr
TON - November 2017, Vol 10, No 6 published on November 27, 2017 in Conference Correspondent
Last modified: December 12, 2016